Plain language summary of the management of certain side effects of teclistamab in people with multiple myeloma [0.03%]
关于teclistamab治疗多发性骨髓瘤时某些不良反应管理的通俗概述
Thomas G Martin,Niels W C J van de Donk,Paula Rodríguez-Otero et al.
Thomas G Martin et al.
Avelumab real-world use in advanced Merkel cell carcinoma: a systematic review and non-comparative meta-analysis [0.03%]
阿维鲁单抗在晚期默克尔细胞癌中的真实世界应用：系统性回顾和非比较性meta分析
Andreas Freitag,Zhiyi Lan,Hoora Moradian et al.
Andreas Freitag et al.
Aim: Programmed death (ligand) 1 inhibitors (e.g., avelumab, pembrolizumab, and retifanlimab) are first-line treatment options for patients with locally advanced or metastatic Merkel cell carcinoma (MCC). In the absence o...
Machine learning-based prediction of central lymph node metastasis in unifocal papillary thyroid microcarcinoma [0.03%]
基于机器学习的单发病灶乳头状甲状腺微小癌中央区淋巴结转移预测
Xi Dai,Xiaoyu Zhou,Yating Ruan et al.
Xi Dai et al.
Objective: This study aims to develop a machine learning (ML) model to predict the risk of central lymph node metastasis (CLNM) in patients with papillary thyroid microcarcinoma (PTMC) using a combination of clinical and ...
Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer [0.03%]
止吐预防对减少HER2+/HER2低乳腺癌曲妥珠单抗德鲁克斯剂量调整的影响
Junghoon Shin,Ji-Yeon Kim,Hee Kyung Ahn et al.
Junghoon Shin et al.
Background: Avoiding unnecessary dose reductions is important for patients with advanced breast cancer (ABC) receiving trastuzumab deruxtecan (T-DXd). Nausea and vomiting, the most common adverse events of T-DXd, frequent...
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy [0.03%]
阿特朱单抗/贝伐珠单抗治疗肝细胞癌患者的特征及疗效：二线疗法亚组分析
Amit G Singal,Kirhan Özgürdal,Zdravko Vassilev et al.
Amit G Singal et al.
Background: Atezolizumab plus bevacizumab (atezo+bev) is a standard-of-care 1L treatment for unresectable hepatocellular carcinoma (uHCC). Understanding its adoption and use, clinical outcomes, and subsequent therapies ar...
Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel [0.03%]
lorlatinib治疗ALK阳性晚期非小细胞肺癌(atypical)的安全性特征及意大利专家组管理建议
Andrea Ardizzoni,Diego Cortinovis,Bruno Gori et al.
Andrea Ardizzoni et al.
Lorlatinib is a third-generation tyrosine kinase inhibitor approved for first- and second-line treatment of ALK-positive advanced non-small cell lung cancer. The CROWN study demonstrated that first-line lorlatinib significantly improves pro...
Matching-adjusted indirect treatment comparison of A+AVD vs PET-guided ABVD in newly diagnosed advanced Hodgkin lymphoma [0.03%]
一种匹配调整的间接治疗比较：A+AVD与PET指导下的ABVD在新诊断的晚期霍奇金淋巴瘤中的疗效对比研究
Fjoralba Kristo,Alexa Molinari,Zhiyi Lan et al.
Fjoralba Kristo et al.
Aims: The study team investigated the relative efficacy of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) versus positron emission tomography (PET)-guided doxorubicin, bleomycin, vinblastine, and d...
Real-world management of oral mucositis/stomatitis among patients with advanced non-small cell lung cancer (NSCLC) or breast cancer (BC) [0.03%]
晚期非小细胞肺癌(NSCLC)或乳腺癌(BC)患者口腔黏膜炎/口炎的现实世界管理
Marvin Nguyen,Ruchit Shah,Jon Apple et al.
Marvin Nguyen et al.
Aims: To describe United States real-world oral mucositis/stomatitis (OM/S) management for patients with non-small cell lung cancer (NSCLC) or breast cancer (BC) and document physician awareness of OM/S guidelines, risk f...
Feasibility of an early versus delayed rehabilitation intervention in patients with lung cancer on cancer-related fatigue: a pilot RCT [0.03%]
早期康复干预与延迟康复干预对肺癌相关疲劳的影响：一项随机对照试验的研究报告
Stefania Fugazzaro,Carlotta Mainini,Alessia Pecorari et al.
Stefania Fugazzaro et al.
Background: Cancer-related fatigue (CRF) reduces physical performance and quality of life (QoL). Some authors suggest including moderate-intensity physical exercise to manage CRF; however, the optimal timing to offer reha...
MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors [0.03%]
I/IIa期，多中心，首次人体，开放标签I期/I期b期临床试验：评估MDX2001单药治疗晚期实体瘤患者在临床上的安全性、耐受性和抗肿瘤活性（项目代码：MDX-2001-101）
Ecaterina Dumbrava,Anna Minchom,Jason Henry et al.
Ecaterina Dumbrava et al.
MDX2001 is a tetraspecific T-cell engager-expander antibody engineered to recognize four distinct antigens: cellular mesenchymal-epithelial transition factor (c-MET) and trophoblast antigen 2 (TROP2) to direct T cells to tumor cells, CD3 to...